ECL’s Access to Medicines Advocacy 

Policy Recommendations

Joint recommendations on HTA and its final steps – June 2021

Reflection Statement on medicines shortages & Common Amendments to the proposed Regulation on the role of the EMA – June 2021

Short statement on the reflection paper on forecasting demand for
medicinal products in the EU/EEA  –  June 2021

Civil society recommendations for improving the Orphan and the Paediatric Regulations  –  May 2021

ECL’s contribution to the 2021 WHO Fair Pricing Forum  –  May 2021

Short statement on the Council of the EU’s latest Health Technology Assessment (HTA) proposal –  March 2021

Short statement on the outcome of the Aspen Case AT.40394 –  February 2021

Short statement on Europe’s Beating Cancer Plan  –  February 2021

Short statement on Europe’s Pharmaceutical Strategy  –  November 2020

What is a fair price? Position Paper  –  September 2020

Launch event recording

Position paper on Europe’s Pharmaceutical Strategy  –  August 2020

Joint recommendations towards fair prices of medicines in Europe  –  July 2020

Joint Position Paper on Medicines Shortages  & Amendments to INI on Shortages –  April 2020

 

Access to Treatment – A Core Component of ECL’s Vision for Europe’s Beating Cancer Plan  (pg 12-18) –  February 2020

ECL & EORTC joint statement on the judgments of the CJEU in Cases C-175/18, C-178/18 P
PTC Therapeutics International v EMA  –  January 2020

Position Paper on the outcomes of WHO resolution on ‘Improving the transparency of markets for medicines, vaccines and other health products’– June 2019

LET’S TALK ACCESS! White Paper on Tackling Challenges in Access to Medicines – October 2018

ECL analysis on CAR T-Cell Therapies pricing – June 2018

ECL position paper  on European Cooperation on Health Technology Assessment (HTA) – June 2018

Stakeholder Consultations

Support of Aspen commitments Case AT.40394-Aspen   –  September 2020

Submission to EU Pharmaceutical Strategy Consultation  –  June & September 2020

HMA/EMA Joint Network Strategy 2025 Consultation  –  August 2020

Feedback to EU Intellectual Property Action Plan  –  July 2020

Feedback to Pilot Project on Market Launch of Centrally Authorised Medicines  –  July 2020

ECL submission to a public consultation on Europe’s Beating Cancer Plan – March & May 2020

ECL submission to a public consultation on EMA Regulatory Science 2025 – June 2019

ECL comments  within the EU Ombudsman’s inquiry OI/7/2017/KR – Public consultation – December 2018

Letters to Decision-Makers

Joint letter to Commissioners Breton and Kyriakides regarding safety stocks for medicines – February 2020

Letter to European ministers of health in support of Italian draft resolution on transparency in pricing of medicines, vaccines and health technologies – May 2019

Joint Open Letter to the European Commission on investigation of root causes of medicine shortages – May 2019

Letter to national ministers of health on the role of pricing transparency and inter-governmental knowledge-sharing in access to affordable medicines – December 2017

Letter to Commissioner Vestager on the role of EU competition policy in equal access to Medicines – February 2017

Press Releases & Statements 

Endorsement of the Porto Declaration on Cancer Research – June 2021

Common Note on the European Parliament’s report on medicine shortages – September 2020

Publication of  ‘What’s A Fair Price?’ Paper – September 2020

Publication of Let’s Talk Access White Paper – October 2018

Reaction to BMJ Study on efficacy of cancer medicines – October 2017

Infographics & Visuals

ECL Recommentdations for European HTA Cooperation

ECL Access to Medicines Task Force Declaration of Intent